Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils
Kynurenic acid (KynA), a broad spectrum antagonist of excitatory amino acid receptors, may serve as a protective agent in neurological disorders. The potential anti-inflammatory effect of KynA in human leukocytes has not been characterized. The aim of this study was to compare the effects of KynA with those of a new analogue, 2-(2-N,N-dimethylaminoethylamine-1-carbonyl)-1H-quinolin-4-one hydrochloride on tumour necrosis factor-α (TNF-α) production and high mobility group box protein 1 (HMGB1) secretion. The effects of KynA on granulocyte activation were investigated via the secretion of human neutrophil peptide 1–3 (HNP1–3). Peripheral blood mononuclear cells and granulocytes or CD14 positive monocytes were applied as effector cells, or whole blood cultures were used. TNF-α, HMGB1 and HNP1–3 concentrations were determined by ELISA, TNF-α and HNP1–3 mRNA expressions were quantified by reverse transcription PCR. KynA attenuated the TNF-α production of human mononuclear cells activated by heat-inactivated Staphylococcus aureus, inhibiting TNF-α production at the transcription level. Furthermore, KynA diminished HMGB1 secretion by U 937 monocytic cells and by peripheral blood monocytes. KynA inhibited the HNP1–3 secretion in whole blood and in granulocyte cultures. The suppressive effect of the KynA analogue was more potent than that of an equimolar concentration KynA in TNF-α, HMGB1 and HNP1–3 inhibition. These results suggest that the new KynA analogue has a more potent immunoregulatory effect than KynA on human mononuclear cells, monocytes and granulocytes and indicate the potential benefits of further exploration of its uses in human inflammatory disease.
KeywordsKynurenic acid TNF-α HMGB1 Defensin-α Monocytes Granulocytes
We thank Mrs. Györgyi Müller for expert technical assistance and Mrs. Zsuzsanna Rosztoczy for skillful administration. This work was supported by Hungarian Research Grant OTKA K67889/5K540.
- Kiss C, Vecsei L (2005) Neuroprotection and kynurenine system. In: Vecsei L (ed) Kynurenines in the brain: from experiment to clinics. Nova Science, New York, pp 173–191Google Scholar
- Klivenyi P, Toldi J, Vecsei L (2004) Kynurenines in neurodegenerative disorders: therapeutic consideration. In: Vecsei L (ed) Frontiers in clinical neuroscience: neurodegeneration and neuroprotection. Adv Exp Med Biol, vol 541. Kluwer, New York, pp 169–183Google Scholar
- Kocsis AK, SzabolcsA HP, Hofner P, Takács T, Farkas G, BodaK G, Mandi Y (2009b) Plasma concentrations of high-mobility group box protein1, soluble receptor for advanced glycation end products and circulating DNA in patients with acute pancreatitis. Pancreatology 9:383–391PubMedCrossRefGoogle Scholar
- Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, Tracey KJ, Lotze MT, Hackam DJ, Fink MP, Vodovotz Y, Billiar TR (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 293:R1538–R1544PubMedCrossRefGoogle Scholar
- McNearney TA, Ma Y, Chen Y, Taglialatela G, Yin H, Zhang WR, Westlund KN (2010) A peripheral neuroimmune link: glutamate agonists upregulate NMDA NR1 receptor mRNA and protein, vimentin, TNF-alpha, and RANTES in cultured human synoviocytes. Am J Physiol Regul Integr Comp Physiol 298:R584–R598PubMedCrossRefGoogle Scholar
- Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, Ochani M, Ochani K, Yang LH, Hudson L, Lin X, Patel N, Johnson SM, Chavan S, Goldstein RS, Czura CJ, Miller EJ, Al-Abed Y, Traccy KJ, Pavlov VA (2008) Modulation of TNF release by choline requires alpha7 subunit nicotinic acethylcholine receptor-mediated signaling. Mol Med 14:567–574PubMedCrossRefGoogle Scholar
- Varga G, Erces D, Fazekas B, Fulop M, Kovacs T, Kaszaki J, Fulop F, Vecsei L, Boros M (2010) N-Methyl-d-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol Motil 22:217–221PubMedCrossRefGoogle Scholar
- Wang JE, Jorgensen PF, Almlof M, Thiemermann C, Foster SJ, Aasen AO, Solberg R (2000) Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6) and IL-10 production in both T cells and monocytes in a human whole blood model. Infect Immun 68:3965–3970PubMedCrossRefGoogle Scholar
- Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N (2006) Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappa B phosphorylation and nuclear factor-kappa B transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol 146:116–123PubMedCrossRefGoogle Scholar